National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 276688

Case Details

VAERS ID: 276688 (history)  
Age: 11.0  
Gender: Female  
Location: Connecticut  
Vaccinated:2007-02-02
Onset:2007-02-16
   Days after vaccination:14
Submitted: 2007-04-13
   Days after onset:55
Entered: 2007-04-16
   Days after submission:3
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. 0013U / 1 LA / IM

Administered by: Other       Purchased by: Other
Symptoms: Skin lesion, Skin papilloma
SMQs:, Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Died? No
Permanent Disability? No
Recovered? No
ER or Doctor Visit? Yes
Hospitalized? No
Previous Vaccinations:
Other Medications: DIFFERIN
Current Illness: Acne
Preexisting Conditions:
Diagnostic Lab Data: None
CDC Split Type: WAES0703USA03119

Write-up: Information has been received from a licensed practical nurse concerning an 11 year old female with acne who on 17-NOV-2006 was vaccinated IM with a first 0.5 ml dose of GARDASIL (lot# 654741/0013U). On 02-FEB-2007 the patient received a second dose of GARDASIL. Concomitant therapy included adaplalene (DIFFERIN). Two weeks after receiving the second dose, the patient developed wart-like lesions on her hands. It was reported that the physician arranged a dermatologist consult for the patient. No diagnostic laboratory studies were involved. At the time of this report, the patient''s outcome was unknown. No product quality complaint was involved. Additional information has been requested. This is in follow-up to report (s) previously submitted on 4/13/2007. Information has been received from an advanced practice registered nurse concerning an 11 year old female with acne on 17-NOV-2006 was vaccinated IM with a first dose 0.5 ml of GARDASIL vaccine (lo#654741/0013U). On 02-FEB-2007 the patient was vaccinated IM, in the left arm with a second dose of 0.5 ml of GARDASIL vaccine (lot #653978/0955F0. Concomitant threrapy included DIFFERIN. Two weeks after receiving the second dose, the patient developed 12-13 warts on her hands. It was reported that the physician arranged a dermatologist consult for the patient. No diagnostic laboratory studies were involved. At the time of this report, the patient''s outcome was unknown. No product quality complaint was involved. Additional information is not expected.


New Search

Link To This Search Result:

http://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=276688


Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166